Date	Headline
Jul 31, 2018	PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
Jul 24, 2018	PROVECTUS BIOPHARMACEUTICALS ANNOUNCES ACCEPTANCE OF PV-10 POSTER PRESENTATION AT ESMO 2018 CONGRESS
Jul 10, 2018	PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
Jun 19, 2018	PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE
May 17, 2018	PROVECTUS BIOPHARMACEUTICALS AND PEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTICS INVESTIGATORS' CONSORTIUM (POETIC) ANNOUNCE PV-10 ABSTRACT AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

Our Contact Form	Mailing Address
Telephone: +1 (866) 594-5999 Fax: +1 (866) 998-0005 info@pvct.com	Provectus Biopharmaceuticals, Inc. 10025 Investment Drive, Suite 250 Knoxville, TN 37932
Investor Relations	Media Relations
Provectus Biopharmaceuticals, Inc. Email: investorrelations@pvct.com Phone: +1 (866) 594-5999 x1	Provectus Biopharmaceuticals, Inc. E-mail: mediarelations@pvct.com Phone: +1 (866) 594-5999 x4
Transfer Agent
(i.e. stockholder records, transfer, change of address, etc.) Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, NY 11717 E-mail: shareholder@broadridge.com Telephone: +1 (877) 830-4936 Fax: +1 (215) 553-5402

Filing Date	Form Type	Description	View
Aug 07, 2018	10-Q	Quarterly report	html pdf xbrl
May 09, 2018	10-Q	Quarterly report	html pdf xbrl
Mar 23, 2018	10-K	Annual report	html pdf xbrl
Nov 08, 2017	10-Q	Quarterly report	html pdf xbrl
Aug 09, 2017	10-Q	Quarterly report	html pdf xbrl

Company Overview